Related Experiment Video
Updated: May 10, 2026
11:20
Comparative in vivo Study of gp96 Adjuvanticity in the Frog Xenopus laevis
Published on: September 16, 2010
Placenta-derived gp96 as a multivalent prophylactic cancer vaccine
Bao Zhao1, Yanzhong Wang, Bo Wu
1CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Scientific Reports
|June 7, 2013
Summary
Placenta-derived heat shock protein gp96 shows promise as a novel cancer vaccine. This protein induces anti-tumor T cell responses and provides protection against various cancers in preclinical models.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Designing effective prophylactic cancer vaccines is challenging due to the need for safe and immunogenic cancer antigens.
- Cancer and embryonic tissues share antigen expression patterns, suggesting potential sources for vaccine development.
Purpose of the Study:
- To investigate the potential of placenta-derived heat shock protein gp96 as a prophylactic cancer vaccine.
- To evaluate the anti-tumor immune responses induced by placental gp96.
Main Methods:
- Immunization of mice and rats with placental gp96.
- Assessment of protection against transplantable and chemically induced tumors.
- Evaluation of tumor growth in genetically engineered mouse models.
- Analysis of T cell responses specific to tumor-associated antigens like HER2 and MUC1.
Main Results:
- Placental gp96 provided partial protection and long-term anti-tumor immunity against melanoma and breast tumors in mice.
- Complete protection was observed against 7,12-dimethylbenz(a)-anthracene (DMBA)-induced mammary tumors in rats.
- Significant reduction in the occurrence and growth of autochthonous breast tumors in HER2 transgenic mice.
- Placental gp96 activated HER2- and MUC1-specific T cell responses by binding to tumor-associated antigens.
Conclusions:
- Placental gp96 exhibits novel immunogenicity and potential as a multivalent cancer vaccine.
- This approach offers a promising strategy for developing prophylactic cancer vaccines by targeting shared antigens between cancer and embryonic tissues.
